|
|
Blood, 15 November 2005, Vol. 106, No. 10, pp. 3618-3620.
Prepublished online as a Blood First Edition Paper on July 26, 2005; DOI 10.1182/blood-2005-05-2174.
Previous Article | Next Article 
Submitted May 31, 2005
Accepted July 10, 2005
Prevalence, clinical profile and prognosis of NPM mutations in AML with normal karyotype
Nicolas Boissel, Aline Renneville, Valeria Biggio, Nathalie Philippe, Xavier Thomas, Jean-Michel Cayuela, Christine Terre, Isabelle Tigaud, Sylvie Castaigne, Emmanuel Raffoux, Stephane de Botton, Pierre Fenaux, Herve Dombret, and Claude Preudomme*
Service d'Hematologie Adulte, Hopital Saint-Louis, Paris, France
Laboratoire d'Hematologie A, Hopital Calmettes, Lille, France
Service d'Hematologie Clinique, Hopital Edouard Herriot, Lyon, France
Laboratoire Central d'Hematologie, Hopital Saint-Louis, Paris, France
Laboratoire de Cytogenetique, Hopital de Versailles, Versailles, France
Laboratoire d'Hematologie et de Cytogenetique, Hopital Edouard Herriot, Lyon, France
Service d'Onco-Hematologie, Hopital de Versailles, Versailles, France
Service des Maladies du Sang, CHU de Lille, Lille, France
Service d'Hematologie Clinique, Hopital Avicennes, Bibigny, France
* Corresponding author; email: cpreudhomme{at}chru-lille.fr.
NPM mutation has been reported as the most frequent mutation in AML, especially in the presence of a normal karyotype. In this subgroup of intermediate risk AML, the identification of other gene mutations (e.g. FLT3, CEBPA) have helped to refine the prognosis. This study explored the prevalence and the prognostic impact of NPM mutations in a cohort of 106 patients with normal karyotype AML. NPM exon 12 mutations were detected by PCR and fragment analysis for the insertion/deletion globally resulting in 4 base-pairs insertion. NPM mutations were detected in 47% of patients and were associated with a high white blood cell count, involvement of the monocytic lineage (M4/M5), and a decreased prevalence of CEBPA mutations. Complete remission rate and long-term outcome did not differ between NPM mutated and NPM non-mutated patients. Prospective studies are needed to confirm the definitive place of NPM mutation detection to predict AML response to therapy.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. B. Micol, N. Boissel, A. Renneville, S. Castaigne, C. Gardin, C. Preudhomme, and H. Dombret
The role of cytogenetic abnormalities in acute myeloid leukemia with NPM1 mutations and no FLT3 internal tandem duplication
Blood,
November 12, 2009;
114(20):
4601 - 4602.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Preudhomme, A. Renneville, V. Bourdon, N. Philippe, C. Roche-Lestienne, N. Boissel, N. Dhedin, J.-M. Andre, P. Cornillet-Lefebvre, A. Baruchel, et al.
High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder
Blood,
May 28, 2009;
113(22):
5583 - 5587.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Schneider, E. Hoster, M. Unterhalt, S. Schneider, A. Dufour, T. Benthaus, G. Mellert, E. Zellmeier, S. K. Bohlander, M. Feuring-Buske, et al.
NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)
Blood,
May 21, 2009;
113(21):
5250 - 5253.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Renneville, N. Boissel, N. Gachard, D. Naguib, C. Bastard, S. de Botton, O. Nibourel, C. Pautas, O. Reman, X. Thomas, et al.
The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication
Blood,
May 21, 2009;
113(21):
5090 - 5093.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Marcucci, K. Maharry, M. D. Radmacher, K. Mrozek, T. Vukosavljevic, P. Paschka, S. P. Whitman, C. Langer, C. D. Baldus, C.-G. Liu, et al.
Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study
J. Clin. Oncol.,
November 1, 2008;
26(31):
5078 - 5087.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Lo-Coco, A. Cuneo, F. Pane, D. Cilloni, D. Diverio, M. Mancini, N. Testoni, A. Bardi, B. Izzo, N. Bolli, et al.
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia
Haematologica,
July 1, 2008;
93(7):
1017 - 1024.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Lowenberg
Acute Myeloid Leukemia: The Challenge of Capturing Disease Variety
Hematology,
January 1, 2008;
2008(1):
1 - 11.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Palmisano, T. Grafone, E. Ottaviani, N. Testoni, M. Baccarani, and G. Martinelli
NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia
Haematologica,
September 1, 2007;
92(9):
1268 - 1269.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Brown, E. McIntyre, R. Rau, S. Meshinchi, N. Lacayo, G. Dahl, T. A. Alonzo, M. Chang, R. J. Arceci, and D. Small
The incidence and clinical significance of nucleophosmin mutations in childhood AML
Blood,
August 1, 2007;
110(3):
979 - 985.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Li, D. P. Sejas, S. Burma, D. J. Chen, and Q. Pang
Nucleophosmin suppresses oncogene-induced apoptosis and senescence and enhances oncogenic cooperation in cells with genomic instability
Carcinogenesis,
June 1, 2007;
28(6):
1163 - 1170.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Falini, I. Nicoletti, N. Bolli, M. P. Martelli, A. Liso, P. Gorello, F. Mandelli, C. Mecucci, and M. F. Martelli
Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias
Haematologica,
April 1, 2007;
92(4):
519 - 532.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Falini, I. Nicoletti, M. F. Martelli, and C. Mecucci
Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features
Blood,
February 1, 2007;
109(3):
874 - 885.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Mrozek, G. Marcucci, P. Paschka, S. P. Whitman, and C. D. Bloomfield
Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?
Blood,
January 15, 2007;
109(2):
431 - 448.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Dohner
Implication of the Molecular Characterization of Acute Myeloid Leukemia
Hematology,
January 1, 2007;
2007(1):
412 - 419.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Pasqualucci, A. Liso, M. P. Martelli, N. Bolli, R. Pacini, A. Tabarrini, M. Carini, B. Bigerna, A. Pucciarini, R. Mannucci, et al.
Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: impact on WHO classification
Blood,
December 15, 2006;
108(13):
4146 - 4155.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Falini, M. P. Martelli, N. Bolli, R. Bonasso, E. Ghia, M. T. Pallotta, D. Diverio, I. Nicoletti, R. Pacini, A. Tabarrini, et al.
Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia
Blood,
September 15, 2006;
108(6):
1999 - 2005.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Camos, J. Esteve, P. Jares, D. Colomer, M. Rozman, N. Villamor, D. Costa, A. Carrio, J. Nomdedeu, E. Montserrat, et al.
Gene Expression Profiling of Acute Myeloid Leukemia with Translocation t(8;16)(p11;p13) and MYST3-CREBBP Rearrangement Reveals a Distinctive Signature with a Specific Pattern of HOX Gene Expression.
Cancer Res.,
July 15, 2006;
66(14):
6947 - 6954.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. S. Wilson, G. S. Davidson, S. B. Martin, E. Andries, J. Potter, R. Harvey, K. Ar, Y. Xu, K. J. Kopecky, D. P. Ankerst, et al.
Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction
Blood,
July 15, 2006;
108(2):
685 - 696.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Li, D. P. Sejas, R. Rani, T. Koretsky, G. C. Bagby, and Q. Pang
Nucleophosmin Regulates Cell Cycle Progression and Stress Response in Hematopoietic Stem/Progenitor Cells
J. Biol. Chem.,
June 16, 2006;
281(24):
16536 - 16545.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Falini, N. Bolli, J. Shan, M. P. Martelli, A. Liso, A. Pucciarini, B. Bigerna, L. Pasqualucci, R. Mannucci, R. Rosati, et al.
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML
Blood,
June 1, 2006;
107(11):
4514 - 4523.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Thiede, S. Koch, E. Creutzig, C. Steudel, T. Illmer, M. Schaich, G. Ehninger, and for the Deutsche Studieninitiative Leukamie (DSIL)
Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)
Blood,
May 15, 2006;
107(10):
4011 - 4020.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Roti, R. Rosati, R. Bonasso, P. Gorello, D. Diverio, M. F. Martelli, B. Falini, C. Mecucci, and for the Gruppo Italiano Malattie Ematologiche dell
Denaturing High-Performance Liquid Chromatography: A Valid Approach for Identifying NPM1 Mutations in Acute Myeloid Leukemia
J. Mol. Diagn.,
May 1, 2006;
8(2):
254 - 259.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W.-C. Chou, J.-L. Tang, L.-I. Lin, M. Yao, W. Tsay, C.-Y. Chen, S.-J. Wu, C.-F. Huang, R.-J. Chiou, M.-H. Tseng, et al.
Nucleophosmin Mutations in De novo Acute Myeloid Leukemia: The Age-Dependent Incidences and the Stability during Disease Evolution.
Cancer Res.,
March 15, 2006;
66(6):
3310 - 3316.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Mrozek and C. D. Bloomfield
Chromosome Aberrations, Gene Mutations and Expression Changes, and Prognosis in Adult Acute Myeloid Leukemia
Hematology,
January 1, 2006;
2006(1):
169 - 177.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|